• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Acarix

0.26 SEK

-1.12 %

Less than 1K followers

ACARIX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.12 %
-2.76 %
-7.03 %
-1.31 %
-5.54 %
-4.34 %
-51.57 %
-74.35 %
-96.42 %

Acarix is a diagnostics company. The company has developed a technology that enables the identification of coronary artery disease. The company's product is a non-invasive test that is applied with a patch to the patient to analyze sounds from the heart. The business is conducted primarily within the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. The headquarters are located in Malmö.

Read more
Market cap
319.4M SEK
Turnover
84.2K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Forum discussions
On my journey in search of a new Revenio, in a country where vague Finland-Swedish was spoken and which was ruled by Carl XVI Gustaf, I came across a company called Acarix. And I’m not comparing this to be a new Revenio. For the diagnosis of coronary artery disease, a common basic...
9/8/2021, 5:11 AM
by Fisu
9
Expected SEK 79 million share issue now underway: https://acarix.com/wp-content/uploads/2021/11/acarixpralmeria-prospekteng.pdf
12/6/2021, 12:06 AM
by Pohjolan Eka
3
Tärkeimmät talousuutiset | Kauppalehti – 27 Jun 19 Acarix CADScor®System included in NICE guidelines (UK) Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä. Here’s a slightly older bulletin. An interesting product, which has...
9/8/2021, 7:32 AM
by PP2020
3
Interesting that the analyst firm is also an advisor.. Are they also an investor?
9/8/2021, 5:33 AM
by Yoda
3
Redeye’s website does have a Disclosures section for the company in question, which states whether Redeye owns the company. In this case, it does not. redeye.se Acarix Disclosures - Redeye Discover the latest equity research on Acarix.
9/8/2021, 2:45 PM
by Llopardi
2
PubMed Economic Analysis of the CADScor System for Ruling Out Coronary Artery... The CADScor System is a potentially cost-saving test for the diagnosis of CAD. When initiated before the use of non-invasive cardiac imaging tests such as computed tomography coronary angiography, the...
9/8/2021, 5:40 AM
by PP2020
2
News from America has arrived; I don’t know how to post it here. Thanks in advance
10/27/2021, 11:02 AM
by Hollitupa
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.8.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

Regulatory press release17.06.2026 klo 17.30

Announcement from the annual general meeting in Acarix AB

Acarix
Regulatory press release16.06.2026 klo 20.00

Proposals of the Nomination Committee for the Annual General Meeting of Acarix AB (publ) on June 17, 2026

Acarix
Press release19.05.2026 klo 12.12

Redeye: Acarix (Q1 Review): Continued US traction and improved cost base

Acarix

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release18.05.2026 klo 23.30

NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB

Acarix
Regulatory press release18.05.2026 klo 09.00

Acarix Publishes Interim Report, January – March 2026

Acarix
Regulatory press release04.05.2026 klo 15.23

Acarix Changes Publication Date for Q1 2026 Interim Report

Acarix
Regulatory press release15.04.2026 klo 14.00

Acarix AB’s Annual Report 2025

Acarix
Press release07.04.2026 klo 14.00

ACARIX PRESENTS ABSTRACT AT ACC.26 HIGHLIGHTING CADSCOR® SYSTEM'S DIAGNOSTIC UTILITY COMPARED TO STANDARD STRESS TESTS IN CHEST PAIN PATIENTS

Acarix
Press release13.02.2026 klo 14.05

Redeye: Acarix (Q4 review): A solid end to 2025

Acarix
Regulatory press release12.02.2026 klo 09.00

Acarix Publishes Year-End Report 2025

Acarix
Press release11.02.2026 klo 10.20

Acarix Announces New Distribution Partner in Saudi Arabia for the CADScor System

Acarix
Press release04.02.2026 klo 10.20

Acarix Receives EU MDR Certification for the CADScor®System

Acarix
Regulatory press release08.12.2025 klo 09.47

ACARIX CARRIES OUT A DIRECTED SHARE ISSUE OF APPROX. SEK 33.4 MILLION

Acarix
Press release06.11.2025 klo 09.45

Invitation to presentation of Acarix´s third quarter 2025 report

Acarix
Regulatory press release06.11.2025 klo 09.00

Acarix Publishes Interim Report, Third quarter 2025

Acarix
Regulatory press release27.10.2025 klo 16.35

Announcement from the general meeting in Acarix AB

Acarix
Regulatory press release24.10.2025 klo 16.15

Acarix AB changes Certified Adviser to Tapper Partners AB

Acarix
Press release17.10.2025 klo 09.30

Acarix responds to G-BA decision on reimbursement in the German market

Acarix
Regulatory press release09.10.2025 klo 13.15

NOTICE OF EXTRAORDINARY GENERAL MEETING IN ACARIX AB

Acarix
Press release07.10.2025 klo 10.31

Acarix CADScor® System Gains HealthChoice Reimbursement Coverage

Acarix